What it's for (Indications)
- Dinoprost, as prostaglandin F2-alpha, is primarily indicated for its potent uterotonic effects, which include the induction of uterine contractions and cervical ripening.
- In clinical settings, its primary uses revolve around obstetric applications, specifically for the termination of pregnancy in cases of missed abortion, incomplete abortion, or for therapeutic abortion where medically indicated.
- It has also been explored and utilized in the management of refractory postpartum hemorrhage, particularly when conventional oxytocic agents like oxytocin are insufficient or contraindicated, due to its direct action on uterine smooth muscle to promote hemostasis.
- Its use necessitates careful consideration of the patient's medical history and current obstetric status, always under strict medical supervision in a hospital setting.
- The powerful contractile effects make it a critical agent in situations requiring rapid and forceful uterine action and is exclusively reserved for specialized medical environments.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of dinoprost varies significantly depending on the specific indication, route of administration, and the patient's clinical response. For the induction of abortion, it has historically been administered via intra-amniotic or extra-amniotic routes, with doses typically ranging from a few milligrams to tens of milligrams, administered as a single dose or repeated at intervals determined by uterine activity and fetal expulsion. When used for the management of postpartum hemorrhage, an intramuscular route is often preferred, typically involving an initial dose of 250 micrograms (0.25 mg) which may be repeated at intervals of 15 to 90 minutes, not exceeding a total cumulative dose, generally up to 2 milligrams (2000 micrograms) over a specific period, to avoid excessive systemic side effects. Dosage adjustments are imperative for patients with underlying medical conditions, and close monitoring of uterine response, vital signs, and adverse effects is critical throughout the administration period, always under strict medical supervision. |
Safety & Warnings
Common Side Effects
- Dinoprost's potent smooth muscle stimulating properties lead to a range of significant side effects, predominantly affecting the gastrointestinal, uterine, and cardiovascular systems.
- Very common adverse reactions include nausea, vomiting, and severe diarrhea, often experienced by a majority of patients due to its effects on intestinal smooth muscle.
- Uterine-related side effects encompass uterine hypertonus, painful uterine contractions, uterine spasm, and, in rare but serious instances, uterine rupture, especially in patients with prior uterine surgery or multiparity.
- Other reported side effects include fever, chills, headache, dizziness, flushing, bronchospasm or asthma exacerbation (particularly in predisposed individuals), transient hypertension, tachycardia, and arrhythmias.
- Less common but serious reactions include pulmonary edema, disseminated intravascular coagulation (DIC), and anaphylactic-type reactions.
- The severity and incidence of side effects are often dose-dependent and require careful monitoring.
Serious Warnings
- Black Box Warning: **WARNING: POTENT UTEROTONIC AGENT WITH SIGNIFICANT RISKS** Dinoprost is a potent uterotonic agent that induces strong uterine contractions, carrying substantial risks, including the potential for uterine hypertonus, uterine rupture, cervical laceration, and significant hemorrhage. Its use is associated with a high incidence of severe gastrointestinal side effects such as nausea, vomiting, and profound diarrhea. Furthermore, dinoprost can precipitate severe bronchospasm, particularly in patients with a history of asthma or other respiratory conditions, and may cause serious cardiovascular events, including transient hypertension, arrhythmias, or myocardial ischemia, especially in individuals with pre-existing cardiac disease. The administration of dinoprost must be performed exclusively in a hospital setting under the direct supervision of obstetric specialists and with immediate access to intensive care facilities for prompt management of potential life-threatening complications. Patients must be carefully selected, and continuous monitoring of uterine activity, maternal vital signs, and potential adverse reactions is absolutely critical throughout the treatment period. This medication should only be used when the benefits outweigh the severe potential risks and only by healthcare professionals trained in its use and management of its adverse effects.
- Dinoprost should be administered with extreme caution and only under the direct supervision of a healthcare professional experienced in obstetric critical care.
- Significant warnings include the potential for severe uterine hypertonus, leading to uterine rupture, cervical laceration, or fetal distress (if pregnancy is viable).
- Patients with a history of asthma, chronic obstructive pulmonary disease, or other respiratory conditions are at increased risk for severe bronchospasm.
- Individuals with cardiovascular disease, including hypertension, hypotension, or cardiac arrhythmias, must be closely monitored due to potential exacerbation.
- Renal and hepatic dysfunction can impair metabolism and excretion, increasing the risk of adverse effects.
- Diabetic patients and those with epilepsy, glaucoma, or a history of pelvic inflammatory disease also require careful assessment and monitoring.
- The risk of disseminated intravascular coagulation (DIC) has been associated with prostaglandin-induced abortion, necessitating close hematological monitoring.
- Administration outside of a fully equipped medical facility is not recommended.
How it Works (Mechanism of Action)
Dinoprost is a naturally occurring prostaglandin F2-alpha (PGF2α), an endogenous fatty acid derivative that acts as a potent smooth muscle stimulant. Its primary mechanism of action involves binding to specific prostaglandin F2α receptors (FP receptors) located on target cells, predominantly within the myometrium. This binding initiates a cascade of intracellular events, including the activation of phospholipase C and subsequent release of intracellular calcium from sarcoplasmic reticulum stores. The increased intracellular calcium concentration directly stimulates the contractile proteins within uterine smooth muscle cells, leading to powerful and sustained uterine contractions. Additionally, dinoprost promotes cervical ripening by inducing collagen degradation and increasing water content in the cervical stroma, facilitating cervical dilatation and effacement, crucial for the expulsion of uterine contents. Its action is distinct from oxytocin, providing an alternative or synergistic mechanism for uterine contraction by directly affecting myometrial contractility.
Commercial Brands (Alternatives)
No other brands found for this formula.